Regenerative Patch Technologies Initiates Phase IIb Trial for Stem Cell-Based Retinal Implant in Geographic Atrophy
核心洞察
Regenerative Patch Technologies (搜索) has treated the first two patients in a Phase IIb clinical trial testing its CPCB-RPE1 stem cell-based retinal implant for advanced dry age-related macular degeneration (搜索).
The Phase I/IIa trial demonstrated promising results with 27% of treated eyes showing greater than 5-letter visual acuity improvement compared to 7% of untreated fellow eyes after a mean follow-up of 36.9 months.
The Phase IIb trial incorporates a cryopreserved formulation of the implant and will test the therapy in patients with less severe disease to confirm its vision-improving potential.
Regenerative Patch Technologies (搜索) LLC (RPT) has announced the treatment of the first two participants in its Phase IIb clinical trial evaluating the CPCB-RPE1 implant for advanced dry age-related macular degeneration (搜索) (AMD). The multicenter, randomized, assessor-masked trial, designated PATCH AMD, represents a significant advancement in developing vision-restoring therapies for geographic atrophy (搜索), the leading cause of blindness in adults.
Phase I/IIa Results Drive Phase IIb Development
The Phase IIb trial builds upon encouraging results from RPT's completed Phase I/IIa study, where patients were followed for a mean of 36.9 months (range 12-54 months). The data revealed that 27% of treated eyes demonstrated greater than 5-letter gains in visual acuity compared to only 7% of untreated fellow eyes. Additionally, a larger proportion of nonimplanted eyes showed greater than 5-letter vision loss (80% versus 47%) compared to treated eyes.
"Based on our Phase I/IIa clinical trial results, the Phase IIb trial provides an opportunity to collect clinical data in patients with less severe disease to confirm the implant's ability to improve vision," said Jane Lebkowski PhD, President of Regenerative Patch Technologies (搜索).
Advanced Cryopreservation Technology
The Phase IIb trial incorporates a significant technological advancement with the use of a cryopreserved formulation of the implant. According to Linc Johnson PhD, Chief Scientific Officer of RPT, "This long-term storage format facilitates shipment to clinical treatment sites where it is thawed immediately before implantation."
The trial is being conducted at multiple sites across California, Illinois, and Texas, with detailed information available at clinicaltrials.gov under study identifier NCT06557460.
Addressing Critical Unmet Medical Need
Geographic atrophy (搜索) represents a substantial medical challenge, affecting 10-20% of people in the United States over age 65. The condition occurs in the advanced dry form of age-related macular degeneration, which affects 90% of people with AMD.
"To date, the only treatments available to patients with geographic atrophy (搜索) involve frequent injections in the eye which simply slow growth of the lesion," explained Suber Huang, MD, MBA, FASRS, Chief Executive Officer of the Retina Center of Ohio. "The development of a therapy that safely improves vision would be a major breakthrough for the field."
Innovative Bioengineered Implant Technology
The CPCB-RPE1 implant represents a sophisticated bioengineering approach, consisting of stem cell-derived retinal pigmented epithelial (RPE) cells positioned on an ultrathin synthetic parylene membrane. The implant is designed to replace the retinal pigmented epithelium (搜索) and Bruch's membrane (搜索) that degenerate in dry AMD.
The deterioration of these critical structures diminishes spatial, metabolic, and growth-factor support essential for retinal photoreceptor survival and function, ultimately leading to vision loss and blindness. The CPCB-RPE1 implant serves to replace the damaged RPE cell layer and Bruch's membrane (搜索) specifically in the geographic atrophy (搜索) region.
Collaborative Development and Funding
The technology underlying the CPCB-RPE1 implant is exclusively licensed to RPT from the University of Southern California Stevens Center for Innovation, the California Institute of Technology, and University of California, Santa Barbara. The clinical trial has received critical funding support from the California Institute for Regenerative Medicine (搜索) (CIRM), the Marcus Foundation, and the University of Southern California.